MA26.01 Accumulation of Concomitant Mutations Involved in Drug Resistance in the Sequential ALK TKI Treatments of ALK-Positive NSCLC

S. Lu; Y. Yu; Y. Ding; X. Wu; H. Bao; Y.W. Shao

首页> 外文期刊>Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer >MA26.01 Accumulation of Concomitant Mutations Involved in Drug Resistance in the Sequential ALK TKI Treatments of ALK-Positive NSCLC

【24h】

MA26.01 Accumulation of Concomitant Mutations Involved in Drug Resistance in the Sequential ALK TKI Treatments of ALK-Positive NSCLC

机译：MA26.01在ALK阳性NMSCLC的顺序ALK TKI治疗中累积涉及耐药性抗药性的致力突变

获取原文

获取原文并翻译 | 示例

获取外文期刊封面封底 >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer》 |2018年第10期|共1页
作者
S. Lu; Y. Yu; Y. Ding; X. Wu; H. Bao; Y.W. Shao;
展开▼
作者单位

Shanghai Lung Cancer Center Shanghai Chest Hospital Shanghai Jiao Tong University Shanghai;

Shanghai Lung Cancer Center Shanghai Chest Hospital Shanghai Jiao Tong University Shanghai;

Translational Medicine Research Institute Geneseeq Technology Inc;

Translational Medicine Research Institute Geneseeq Technology Inc;

Medical Department Nanjing Geneseeq Technology Inc;

Translational Medicine Research Institute Geneseeq Technology Inc;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类肿瘤学;
关键词

相似文献

外文文献
中文文献
专利

1. MA26.01 Accumulation of Concomitant Mutations Involved in Drug Resistance in the Sequential ALK TKI Treatments of ALK-Positive NSCLC [J] . S. Lu, Y. Yu, Y. Ding, Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer . 2018,第10期

机译：MA26.01在ALK阳性NMSCLC的顺序ALK TKI治疗中累积涉及耐药性抗药性的致力突变
2. P3.08-18 Changing Resistance Mechanisms in Rebiopsies of ALK-Positive NSCLC During Multiple Lines of Therapy: ALK/BRAF-Mutations Followed By EMT [J] . E. Urbanska, L. Melchior, K. De Stricker, Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer . 2018,第10期

机译：P3.08-18在多条治疗过程中抗阳性NMSCLC抗性的抗性机制：ALK / BRAF-突变后跟EMT
3. Clinical impact of sequential treatment with ALK-TKIs in patients with advanced ALK-positive non-small cell lung cancer: Results of a multicenter analysis [J] . Chiari Rita, Metro Giulio, Iacono Daniela, Lung cancer: Journal of the International Association for the Study of Lung Cancer . 2015,第2期

机译：ALK-TKIs序贯治疗对晚期ALK阳性非小细胞肺癌患者的临床影响：多中心分析结果
4. High throughput multiplexed phosphoproteomics identifies drivers of resistance to ALK inhibitor treatment in lung cancer [C] . Amanda L. Edwards, Luc Friboulet, Rosa Frias, ASMS Conference on Mass Spectrometry and Allied Topics . 2016

机译：高通量复用磷蛋白酶鉴定肺癌抗华抗抑制剂治疗的驱动因素
5. Mutations in the Plasmodium falciparum chloroquine resistance transporter: Balancing drug resistance and fitness. [D] . Petersen, Ines. 2010

机译：恶性疟原虫氯喹抗性转运蛋白中的突变：平衡耐药性和适应性。
6. Changing ALK-TKI-Resistance Mechanisms in Rebiopsies of ALK-Rearranged NSCLC: ALK- and BRAF-Mutations Followed by Epithelial-Mesenchymal Transition [O] . Edyta M. Urbanska, Jens B. Sørensen, Linea C. Melchior, 2020

机译：改变ALK-重新排列的NSCLC的活检中ALK-TKI耐药机制的改变：ALK-和BRAF突变继之以上皮-间质转化。
7. Changing ALK-TKI-Resistance Mechanisms in Rebiopsies of ALK-Rearranged NSCLC: ALK- and BRAF-Mutations Followed by Epithelial-Mesenchymal Transition [O] . Edyta M. Urbanska, Jens B. Sørensen, Linea C. Melchior, 2020

机译：改变ALK重新排列的NSCLC的REBIOSES中的ALK-TKI抗性机制：ALK和BRAF-突变，然后进行上皮 - 间充质转换

MA26.01 Accumulation of Concomitant Mutations Involved in Drug Resistance in the Sequential ALK TKI Treatments of ALK-Positive NSCLC

著录项

相似文献

相关主题

期刊订阅